

Pharmaceutical Benefits Scheme (PBS) Listings

1 October 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 October 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; severe chronic plaque psoriasis; severe Crohn's disease (paediatric patient); vision threatening non-infectious uveitis; enthesitis/spondylitis related juvenile idiopathic arthritis

Adalimumab (20 mg/0.2 mL injection, 2 x 0.2 mL syringes) (Yuflyma®) is a new strength of biosimilar now listed on the PBS for the treatment of moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, severe chronic plaque psoriasis, moderate to severe Crohn's disease (paediatric patient), vision threatening non-infectious uveitis and enthesitis/spondylitis related juvenile idiopathic arthritis.

Uncontrolled severe asthma; severe chronic spontaneous urticaria

Omalizumab (75 mg/0.5 mL injection, 0.5 mL pen device; 150 mg/mL injection, 1 mL pen device (Omyclo®) is a new form of biosimilar now listed on the PBS for the treatment of uncontrolled severe asthma and severe chronic spontaneous urticaria.

Chronic myeloid leukaemia (CML)

Asciminib, dasatinib, imatinib, nilotinib and ponatinib for the treatment of CML have had changes to their restrictions to align with current clinical practice. There is no change to authority level.

Atypical haemolytic uraemic syndrome (aHUS)

Eculizumab (300 mg/30 mL injection, 30 mL vial) (Soliris®) and ravulizumab (300 mg/3 mL injection, 3 mL vial; 1.1 g/11 mL injection, 11 mL vial) (Ultomiris®) for the treatment of aHUS have had changes to their restrictions. There is no change to authority level.

Chronic severe dry eye disease with keratitis

Ciclosporin (0.1% eye drops, 2 mL) (Vevye®) is now listed on the PBS for the treatment of chronic severe dry eye disease with keratitis. Authority applications for initial treatment for up to the first 180 days of treatment and continuing treatment can be made using the Online PBS Authorities system or by telephone.

Moderate to severe atopic dermatitis

Tacrolimus (0.1% ointment, 30 g) (aZematop®) is now listed on the PBS for the treatment of moderate to severe atopic dermatitis. Authority applications for flare treatment can be made using the Online PBS Authorities system or by telephone.

Severe active rheumatoid arthritis; active giant cell arteritis; systemic juvenile idiopathic arthritis; severe active juvenile idiopathic arthritis

Tocilizumab (162 mg/0.9 mL injection, 4 x 0.9 mL pen devices; 162 mg/0.9 mL injection, 4 x 0.9 mL syringes; 80 mg/4 mL injection, 4 mL vial; 200 mg/10 mL injection, 10 mL vial; 400 mg/20 mL injection, 20 mL vial) (Avtozma®) is a new biosimilar now listed on the PBS for the treatment of severe active rheumatoid arthritis, active giant cell arteritis, systemic juvenile idiopathic arthritis and severe active juvenile idiopathic arthritis.

Amyotrophic lateral sclerosis

Tofersen (100 mg/15 mL injection, 15 mL vial) (Qalsody®) is now listed on the PBS for the treatment of amyotrophic lateral sclerosis. Authority applications for initial, continuing and grandfather treatments can be made using the Online PBS Authorities system or by telephone.

Phenylketonuria

Glycomacropeptide formula with docosahexaenoic acid and low phenylalanine powder for oral liquid, 30 x 40 g sachets (PKU GMPro Delight®) is now listed on the PBS for the treatment of phenylketonuria. It is listed as a Restricted benefit.

Treatment with gonadotrophin releasing hormone (GnRH) agonist

Triptorelin (3.75 mg injection [1 vial] (&) inert substance diluent [2 mL ampoule], 1 pack) (Diphereline®) has had a change to its restriction. It is now listed as an Unrestricted benefit.

1 October 2026 delisted PBS listings

High risk locally advanced carcinoma of the cervix

Pembrolizumab (100 mg/4 mL injection, 4 mL vial) (Keytruda®) for the treatment of high risk locally advanced carcinoma of the cervix has been de-listed. New prescriptions will be needed from 1 October 2026 under the listing for immunotherapy sensitive advanced or metastatic cancer. Prescriptions for treatments are Authority required (STREAMLINED).

Primary hyperoxaluria type 1

Lumasiran (94.5 mg/0.5 mL injection, 0.5 mL vial) (Oxlumo®) for the treatment of primary hyperoxaluria type 1 no longer has a listing for Grandfather arrangements.

Uncontrolled severe asthma

Dupilumab (200 mg/1.14 mL injection, 2 x 1.14 mL pen devices; 200 mg/1.14 mL injection, 2 x 1.14 mL syringes; 300 mg/2 mL injection, 2 x 2 mL syringes; 300 mg/2 mL injection, 2 x 2 mL pen devices) (Dupixent®) no longer has a listing for Grandfather arrangements.

Infections

Cefuroxime (125 mg/5 mL powder for oral liquid, 70 mL) (Zinnat (UK)®) has been de-listed.

IMPORTANT INFORMATION



Stronger Security Coming to PRODA

Services Australia is strengthening PRODA security by introducing **passkeys and authenticator apps** as additional log in options from **10 October 2026**.

Passkeys and authenticator apps provide a more secure, phishing-resistant way to access PRODA, rather than traditional email and password log in methods.

Existing log in methods will remain available during the rollout. **PRODA users do not need to do anything at this stage.**

More information and support materials will be available on **servicesaustralia.gov.au/proda** before the launch.

Please share this information with your staff and clients and look out for further updates as the new security options are introduced.



Integrated clinical and prescribing software

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider.



PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

REMINDERS



PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.



Correct PBS item code

When requesting PBS authorities via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.



Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.



For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.